Tcl1 Transgenic Mice
- Technology Application
- Mouse model for immune system malignancies in B, T and granulocytes cells. Mouse model for B-cell selection, development, maturation, antibody production and signaling responses through PI3-kinase pathways. Mouse model for designing therapeutics against B-cell malignancies and preventing autoantibody production in autoimmune diseases.
- Detailed Technology Description
- UCLA researchers have developed a murine model in which a TCL1 transgene is overexpressed in both B and T cells. These transgenic mice develop Burkitt-like lymphoma and diffuse large B cell lymphoma at 4 months. This phenotype is accompanied by attendant Bcl-6 expression and mutated JH antibody gene segments. Interestingly, TCL1 is a more powerful initiator of B cell malignancies when compared to the low frequency of T cell malignancies with this model. This is mirrored in humans as >85% of human immune system malignancies are B cell derived.
- Others
-
Other Information
To complete a Ready-to-Sign Agreement for this case, please view this document. [PDF]
Background
TCL1 is a protooncogene overexpressed in many mature B cell lymphomas. TCL1 is also expressed in precursor T cells and absent by the CD4+ CD8+ stage of thymocyte development. In B cells, TCL1 is first expressed in pro-B cells, and is completely absent in memory B cells and plasma cells.
Related Materials
Tech ID/UC Case
20525/2002-274-0
Related Cases
2002-274-0
- *Abstract
-
None
- *Principal Investigator
-
Name: Michael Teitell
Department:
Name: Thomas Wall
Department:
- Country/Region
- USA
For more information, please click Here
